Novartis supports promising young scientists who want to improve their chances to attain advanced science degrees.
Don Ganem and his team of infectious disease specialists are working to meet the growing need for new antibiotics, despite major scientific challenges.
This moving personal story about the challenges of living with a rare disease is written by Rocco Falchetto, a biochemist and director of analytical sciences and imaging at the Novartis Institutes for BioMedical Research (NIBR).
Can we learn anything from mice that might help astronauts combat muscle loss in space? Learn how these insights could aid our research of aging:
The word “biopsy” typically conjures images of large needles. Lab technicians—and scientists working to discover new medicines—need enough tissue from a patient to prepare and evaluate a sample.
A childhood fight for survival in Cambodia leads to a desire to help patients see better. Learn more about our ophthalmology researcher.
Over the next 15 years chronic disease like cancer and heart disease will become major killers in Sub-Saharan Africa. A new report from the Economist Intelligence Unit explains why.
Heart failure affects 26 million people worldwide. More people die from heart failure than from some advanced cancers, including breast and bowel cancer.
Rare diseases such as SMA demand collaborative research at the Novartis Institutes for BioMedical Research. Learn more about orphan disease at NIBR.
Spinal muscular atrophy (SMA) is the most common genetic casue of infant and toddler death. NIBR scientists are trying to make a back up gene take up the slack.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.